Please login to the form below

Not currently logged in
Email:
Password:

Teva gains FDA approval for generic Risperdal

The US FDA has granted final approval for Israeli drug company, Teva, to market its generic version of Risperdal, an antipsychotic agent manufactured by Janssen

The US Food and Drug Administration (FDA) has granted final approval for Israeli drug company, Teva, to market its generic version of Risperdal, an antipsychotic agent manufactured by Janssen.

Risperdal is used for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions. Generic versions of Risperdal (risperidone) will carry the same safety warnings as the branded drug, which includes a Boxed Warning about the off-label use of risperidone to treat dementia-related psychosis in older patients, which can lead to a higher risk of death.

"This generic drug approval is another example of the FDA's efforts to increase access to safe and effective generic drugs as soon as the law permits," said Gary Buehler, director of the FDA's Office of Generic Drugs in the Center for Drug Evaluation and Research.

As the first company to request general approval, (through an Abbreviated New Drug Application (ANDA)) Teva has been granted marketing exclusivity for 180 days.

Janssen's parent company, Johnson & Johnson, has launched its own generic version of Risperdal through another of its subsidiary companies, Patriot Pharmaceuticals. This will be a direct competition for Teva's drug.

IMS sales data shows that in the 2007/08 financial year, US sales of Risperdal brought in $42.6bn for Janssen.

1st July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics